This is not a good news at all...I met this guy recently and he is a solid guy...He along with CEO has build this company....This company has a very weak bench and it just got weaker....Just look carefully if there is a second shoe to drop...and a reason for this guy to leave.
Based on one conversation I had with him and his comments in the quarterly CCs, Anderson struck me as a decent guy and I'm sorry to see him go. But there could be a thousand reasons for it and I doubt it will have any impact on the stock price. Unlike a departure of the CEO or the Chief Medical Officer it will have no effect on the managerial or clinical direction of the company.
Interesting that in the PR relating to him, they said Cindy Jacobs, the CMO, is involved in developing phase 2 protocols for OGX-427 in both prostate and bladder cancer. As far as I know, that's the first time they've said they plan to move OGX-427 into a P2 trial in bladder. I realize there's an ongoing P1 trial investigating its use as a monotherapy when infused directly into the bladder. I wonder if the P2 trial will be a randomized test of the same approach.